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Abstract
In diseases such as cancer, Alzheimer’s disease or malaria, disease-related proteins take advantage of the heat 
shock protein (HSP) control system for their own activation or maturation. There is a quest to find inhibitors 
that specifically bind to the HSPs. Here, we report on a novel multiplexed assay system for inhibitor screening 
based on a protein microarray (MA) technique that was developed for routine applications with storable MAs. 
Purified HSPs are printed as full-length proteins on microarrays and used as a drug target for the screening 
of new inhibitors. Derivatives obtained by a combination of biological and chemical synthesis were tested as 
competitors of ATP with a suggested affinity for several HSP proteins which are hHSP from human, AtHSP83 
(Arabidopsis thaliana) and HtpG from Helicobacter pylori. Some of these new derivatives exerted selectivity 
between human and bacterial heat shock proteins. Printed human HSP90 was used to test the binding of denatured 
proteins on the client binding site of human HSP90, since the full-length HSP maintains the capability to bind 
putative clients or cochaperones. Initial data revealed that the microarray application can be used to identify 
directly elevated heat-shock protein levels in cancer cell lysates. We suggest that microarray-based assaying of 
HSP levels can be used as a marker for determining stress levels.
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Background
Heat shock proteins (HSPs) are molecular chaperones, 
which help other proteins to mature and fold to their native 
structure even under extreme environmental conditions. 
HSPs are essential for the maintenance and function of 
the proteome [1-4]. Due to their special key position 
mediating a rescue mechanism, HSPs are targets for drug 
development in diseases such as cancer [5-8]. Inhibitors 
or drugs lower increased cellular HSP90 activity and 
thereby increase misfolded client proteins with oncogenic 
potential that arise as a result from mutations [9-12]. This 
ideally leads to the death of the cell or in special cases to 
the reduction of a pathogen, when a suitable HSP inhibitor 
is present. 
Within this study we used a recently reported HSP 
microarray for the target-oriented screening of HSP 
inhibitors [13]. While in our previous publication [13] the 
microarray was solely used to screen molecules for their 
potential to inhibit the ATP binding sites of HSP90 and 
HtpG, this short communication aims to further broaden 
the range of applications: 
(i) Since the ATP - binding sites exist in all HSP target 
proteins, different target proteins can be examined in 
parallel in a multiplexing approach. The assay is performed 
with tiny amounts per spot (800-1600 picoliters) without 
limiting the sensitivity. The recombinant purified target 
proteins bind labeled ATP; binding and displacement 
by potential inhibitors can be detected optically in 
the microarray format. In this communication, we 
demonstrate the multiplexing capability by using human 
HSP90, bacterial HtpG, and plant-derived HSP83.
(ii) The assay can also be performed with HSP 
originating from cell lysates by directly printing the lysates 
to the microarray. We show that this lysate microarray 
can be used to detect elevated HSP titers and hypothesise 
potential diagnostic applications. 
(iii) Furthermore, HSP interactions with labeled 
proteins/peptides can be detected, resulting in the 
possibility to screen the client binding site of HSP as a 
further potential target site for drug development.
Results and Discussion
Purified HSPs (human HSP90a, plant AtHSP83, H. 
pylori HtpG) have been printed in parallel onto a 
microarray surface. Fluorescently (Cy3) labeled ATP 
directly competed with different natural product derived 
heat shock protein inhibitors. These natural products were 
accessed by a combination of chemical synthesis and 
mutational biosynthesis  [13-15]. The potential inhibitors 
were applied in different concentrations ranging from 
50 µM to 50 pM and the data collected were used to 
calculate IC50 values as described by Schax et al. [13]. 
Figure 2a exemplifies the results of the competition assay 
for purified AtHSP83. It could be demonstrated that an 
efficient competition between labeled ATP and the used 
geldanamycin derivative 17 AAG and bromo-reblastin 
occurs (Fig. 1) as indicated by the calculated IC50 values 
of 291 nM for 17 AAG and 79 nM for bomo-reblastin 
(Fig. 2a). It was demonstrated that compounds 2 and 3 
were also able to effectively displace the labeled ATP from 
purified HSP83 from A. thaliana (Fig. 2a). The results 
of screening several potential inhibitors against human 
and bacterial HSPs are summarized for comparison in 
the heat map shown in Figure 2b. Our results indicate 
that it is possible to compete labeled ATP with different 
efficiencies for different HSPs. Using the HSP microarray 
new compounds that bind specifically to one of the HSPs 
were identified from a small drug library synthesized and 
characterized as described recently [13-15]. 
The HSP microarray has the advantage to allow 
the multiplexed testing of an `HSP-zoo´ composed of 
different HSPs derived from different organisms against 
a large arsenal of potential drugs.
The HSP microarray is a novel miniaturized assay 
system used for determining inhibition of the ATP-
binding pocket in HSPs from human (HSP90α) as well 
as bacterial sources (HtpG from H. pylori) by small 
molecules and this could potentially allow HSP screening 
under high throughput conditions. An important outcome 
of this preliminary study is the observation that drug 
candidates derived from benzoquinone geldanamycin 
Figure 1. Structures of 17 AAG (1) and the non-quinone geldanamycin bromo-reblastin derivative (2) and 
18-dehydrox-19-fluoro-reblastatin (3).
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Figure 2a. Typical displacement assay of Cy3-ATP on AtHSP83 by geldanamycin derivative. 
Purified AtHSP83 was printed on the microarray surface and Cy3-ATP was competed by a 
geldanamycin derivative, synthesis and properties given in Schax et al., [13]. The IC50 value 
was obtained from dose-response curve fittings.
Figure 2b. Heat map of the calculated IC50 values of HSP90α from H. sapiens, HtpG from 
H. pylori and HSP83 from A. thaliana for several tested potential inhibitors in a competitive 
displacement assay. Numbers as indicated have been described before [13]. Different grey tones 
from black to white indicate the potency of the inhibitor. White corresponds strong inhibitory 
effects, whereas black shows no effects for the competition with ATP for the binding pocket. 
Figure 2c. Competitive assay of Cy3-ATP by geldanamycin derivative 18-dehydrox-19-
fluoro-reblastatin [13] on cancer cell lysates. Concentrated human cancer cell lysate obtained 
from cell culture was printed on microarray surface and bound Cy3-ATP was competed by a 
geldanamycin derivative. The IC50 value was obtained from dose-response curve fittings.
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Figure 3. Binding of labeled potential client proteins to HSP90α. Signal intensities were 
analysed at the wavelength 532 nm with a gain of 200.
like 17-AAG are selective between human HSP, plant 
HSPs and bacterial HtpG [13]. This assay will allow 
us to search for small molecules that selectively inhibit 
pathogenic bacterial HSPs [13] and not the human 
HSP90α. 
To explore prospective diagnostic applications of 
the HSP microarray, we have investigated the potential 
of the microarray to directly estimate the HSP level 
by printing of cancer cell lysates. Cancer cell lysates 
were printed on the microarray, and it could be shown 
that the labeled ATP was competed by a geldanamycin 
derivative 18-dehydrox-19-fluoro-reblastatin (Fig. 2c). 
Interestingly, the geldanamycin derivative 18-dehydrox-
19-fluoro-reblastatin (Fig. 1), which is fluorinated at 
the phenyl-ring, is a strong competitor of ATP of all 
investigated HSPs with different displacement potencies 
[13]. This demonstrates the possibility to test individual 
tissues for HSP levels and broadens the applicability of 
the HSP microarray for the diagnostic field using human 
HSPa as a cell stress marker and perhaps also in plant 
tissues. This may also enable the detection of HSP-related 
cancer cells in liquor or tissues after tumor dissection.
While the above mentioned applications of the HSP 
microarray exploit the binding of ATP and corresponding 
inhibitors to the ATP binding site of HSP, HSP offers more 
sites that could be used as drug binding sites. One of these 
sites is the client binding site. To investigate whether the 
full-length human HSP90a printed on the microarray is 
able to bind client proteins, we have screened the binding 
of different proteins in native and denatured form (Fig. 
3). Luciferase, plant calmodulin and bacterial potassium 
channel KcsA were tested as potential client proteins; the 
proteins were purified and labeled with Cy3. Denatured 
proteins were obtained by heat denaturation and binding 
of denatured proteins was compared to binding of native 
proteins. All binding tests were performed under different 
conditions, only the presence of Tween20 enabled binding, 
whereas other detergents (octyl glucosid, triton X100, or 
NP40) or no detergent in the binding buffer did reduce 
client binding completely.
It could be shown that heat denaturation was not 
required for KcsA binding. In case of luciferase, only the 
denatured protein binds to the printed HSP90, while no 
binding of native luciferase was observed. This indicates 
the specific binding of the denatured protein to the client-
binding site of HSP, which is expected to show increased 
binding of denatured and thus misfolded proteins. In 
contrast, denatured or native calmodulin does not bind 
to HSP90. Since HSP90 detects unfolded proteins only, 
a higher heat stability of calmodulin may explain the loss 
of binding. The successful binding of the other proteins 
to HSP indicates that the client-binding site of printed 
HSP90 is active and could serve as an additional target-
site for screening of drug compounds. 
In summary, the described HSP microarray bears the 
potential to screen against HSP derived from further 
sources including other pathogens and plants. Target-
oriented screening was successfully used to estimate 
HSP levels in cancer cell lysates to enable diagnostic 
application, which may serve as a novel stress test. The 
microarray could thus enable a direct testing of tumor 
tissues after dissection from patients. The tissue is 
lysed and printed onto the microarray for determination 
of an inhibitor profile against the complete the ATP 
proteome including elevated protein concentrations of 
Hsp90 in the case of some cancer types. At this point 
it is a diagnostic tool and indicates whether the tumor 
has modifications from TP53 and corresponding HSP 
pathways (50% of all cancer types) with the possibility to 
give a prognosis and choice and for subsequent therapies 
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(this is under development together with the Medical 
High School Hannover, MHH; pers. comm.). This is a 
strategy to develop tools for personalized medicine with 
applications for other dissected materials or liquors from 
patients.  
In addition to the well-characterized ATP binding 
site of HSP90, other HSP90 sites can be tested e.g. by 
binding of client proteins or co-chaperones to improve 
novel drugs against the corresponding binding sites. As 
a main advantage, the concept of the assay is general and 
should be transferable to other ATP-dependent HSPs and 
enzymes. 
Experimental Section
Preparation of geldanamycin derivatives
All geldanamycin derivatives, except for 17-AAG, 
used in this study were obtained as previously reported 
[13, 14]. The synthetic strategy relied on mutasynthesis 
using a mutant strain of S. hygroscopicus var. geldanus 
that was blocked in the biosynthesis of the starter unit, 
3-amino-5-hydroxybenzoic acid (AHBA) [14]. 17-AAG 
and radicicol are commercially available (Biomol).
Protein preparations 
The cDNA of HSP83 from A. thaliana was cloned into 
a petSUMO plasmid, transformed into the Escherichia 
coli Rosetta strain, overexpressed and purified as 
previously described [13]. Synthesis and purification of 
the target proteins HSP90α and HtpG from Helicobacter 
pylori were produced as described before [13] and the 
putative clients were produced in Escherichia coli. 
The bacterial potassium channel was produced and 
purified as described by Barbier et al., [16]. The firefly 
luciferase was obtained after transformation of the 
pBest-Luc (Promega) into Escherichia coli Bl21DE3 
strain and luciferase activity was tested after purification 
as described by [17] The cDNA of calmodulin was 
cloned into pTrcHis2TOPO plasmid, transformed into 
the Escherichia coli Bl21DE3 strain. Purified proteins 
were frozen at a concentration of 1-3 mg ml-1 in liquid 
nitrogen and stored at 80°C.
Direct competitive assay 
The HSP microarray assay was performed as 
described by Schax et al., (2014) using 4 x 5 matrices 
of proteins printed on UniSart® 3D nitro slide (Sartorius 
Stedim Biotech, Göttingen, Germany) using a GeSim 
Nano-Plotter™ (GeSim, Grosserkmannsdorf, Germany) 
equipped with a nanotip pipette. The printed proteins 
on the slides were incubated directly with a mixture of 
100 nM Cy3-ATP and potential inhibitors. The potential 
inhibitors were used in different concentrations ranging 
from 50 µM to 50 pM. The competitive assay was 
carried out in binding buffer (20 mM HEPES-KOH, 
pH 7.3, 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 
0.01% v/v Tween 20, 2 % v/v DMSO, 0.1 mg ml-1 BSA) 
for 16 h at 4°C. Detection of the bound labeled ATP 
was performed using a GenePix 4000B Laser Scanner 
(Molecular Devices, Inc., Sunnyvale, CA, USA) with 
532 nm emission wavelength, laser power 33 %, PMT 
gain 350. Quantification was performed using GenePix 
Pro 6.1 (Molecular Devices, Inc., Sunnyvale, CA, USA) 
and ImaGene 5 of BioDiscovery, Inc.  (Hawthorne, CA, 
USA). The dose-response curves were calculated with 
Origin 7G (OriginLab Corporation, Northampton, MA, 
USA) and fitted with the non-linear function logistic, 
A1=0, A2=1 to obtain IC50 values.
Cell lysate preparation 
The frozen cell pellet consisting of 105 A549 cells 
were thawed on ice and resuspended in 100 µl phosphate 
buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4). Afterwards they 
were mixed with 1 ml of Tris-buffered saline (50 
mM Tris-Cl, pH 7.6, 150 mM NaCl). The lysis of the 
cells was performed on ice with ultrasonic energy 
(pulse duration 0.6 sec, 5 repeats à 30 sec, and break 
in-between of 60 sec). The cell debris were removed 
by centrifugation at 14,000 xg, 4°C and for 30 min. 
Using centrifugal concentrators with a polyethersulfon 
membrane, pore size 0.2 µm (Sartorius Stedim Biotech, 
Göttingen, Germany), the supernatant was filtered for 
3 min at 4°C at 14,000 xg. The collected flow-though 
was concentrated with the help of an ultrafiltration unit 
(polyethersulfon membrane) with a molecular weight 
cut-off of 10 kDa (Sartorius Stedim Biotech, Göttingen, 
Germany) at 14,000 xg for 20 min at 4°C. Furthermore, 
the buffer was exchanged to storage buffer (20 mM Tris-
HCl, pH 7.5, 50 mM KCl, 10% v/v Glycerin, 6 mM 
2-mercaptoethanol) and the concentration of protein in 
the final solution was 2.52 mg ml-1.
Protein labeling and binding to HSP90α 
Purified Luciferase, calmodulin and KcsA were 
labeled with Cy3 (Cy3 Mono-Reactive Dye Pack, 
Amersham, Piscataway, NJ) at a protein concentration of 
1 mg ml-1 as described by Walter et al. [18] and unbound 
label was removed through centrifugal concentrators 
with a cut-off of 10 kDa. The resulting Cy3/protein-ratios 
were 0.04 for calmodulin, 0.33 for KcsA, and 1.65 for 
luciferase. Before incubation with printed HSP90α one 
fraction of the labeled proteins were denatured at 45°C 
for 10 min. Prior incubation with printed HSP90 the 
protein concentration of each potential client protein was 
adjusted to 2 ng µl-1 in 20 mM Hepes, 50 mM KCl, 5 mM 
MgCl2, 30 mM Na2MoO4, 1mM DTT, 0.01 % Tween20, 
1 mg ml-1 BSA, pH 7.3. For each client protein, native 
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and denatured forms of labeled protein were incubated 
onto the microarray over night at 4°C. The microarrays 
washed with 20 mM Hepes, 50 mM KCl, 5 mM MgCl2, 
30 mM Na2MoO4, 1mM DTT, 0.01 % Tween20, 1 mg ml
-1 
BSA, pH 7.3 for 10 min three times. The evaluation of 
the binding and treatment of the slides was performed as 
described before [13].  
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